Novo Nordisk has entered into a strategic collaboration with the American biotechnology firm Septerna for the development of oral small molecules. The goal is the treatment of obesity, type 2 diabetes and other cardiometabolic diseases. The deal is worth up to $2.2 billion. The collaboration focuses on G protein-coupled receptors (GPCRs), including GLP-1, GIP and glucagon receptors. These receptors regulate appetite and blood sugar levels. They are planning four development programs aimed at these goals. Novo Nordisk will cover all research and development costs. The partnership will help diversify the portfolio for injectable therapies.[1]